IBio Overview

  • Status
  • Public

  • Employees
  • 16

Employees

  • Stock Symbol
  • IBIO

Stock Symbol

  • Investments
  • 6

  • Share Price
  • $2.63
  • (As of Friday Closing)

IBio General Information

Description

iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

Contact Information

Website
www.ibioinc.com
Formerly Known As
InB:Biotechnologies, Inc., iBioPharma, Inc.
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 11750 Sorrento Valley Road
  • Suite 200
  • San Diego, CA 92121
  • United States
+1 (979)
Primary Industry
Pharmaceuticals
Stock Exchange
ASE
Vertical(s)
Manufacturing, Digital Health, HealthTech
Corporate Office
  • 11750 Sorrento Valley Road
  • Suite 200
  • San Diego, CA 92121
  • United States
+1 (979)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

IBio Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.63 $2.62 $1.02 - $7.70 $22.7M 8.64M 110K -$6.50

IBio Financials Summary

In Thousands,
USD 		TTM 30-Jun-2024 FY 2024 30-Jun-2024 FY 2023 30-Jun-2023 FY 2022 30-Jun-2022
EV 30,228 30,228 21,674 36,780
Revenue 225 225 0 1,884
EBITDA (14,384) (14,384) (28,061) (25,899)
Net Income (24,907) (24,907) (65,010) (50,391)
Total Assets 28,734 28,734 41,207 99,406
Total Debt 4,460 4,460 17,074 25,766
Public Fundamental Data provided by Morningstar, Inc. disclaimer

IBio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore IBio‘s full profile, request access.

Request a free trial

IBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the d
Pharmaceuticals
San Diego, CA
16 As of 2024

Cumberland, RI
 

Delta, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

IBio Competitors (40)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Tedor Pharma Corporate Backed or Acquired Cumberland, RI
Phyton Biotech Corporate Backed or Acquired Delta, Canada
mAbxience Corporate Backed or Acquired Madrid, Spain
FinVector Corporation Kuopio, Finland
Crescendo Biologics Venture Capital-Backed Cambridge, United Kingdom
You’re viewing 5 of 40 competitors. Get the full list »

IBio Patents

  • 160

    Total Documents Applications and Grants

  • Total Patents Families

  • 89

    Granted

  • 34

    Pending

  • Expiring in next 12 mo

IBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240327515-A1 Anti-cd3 antibodies Pending 31-Mar-2023
US-20240262929-A1 Anti-muc16 antibodies Pending 06-Feb-2023
US-20240228637-A9 Chemokine receptor 8 (ccr8) antibodies Pending 19-Oct-2022
US-20240132604-A1 Chemokine receptor 8 (ccr8) antibodies Pending 19-Oct-2022
US-20240117056-A1 Epidermal growth factor receptor variant iii antibodies Pending 11-Oct-2022 C07K16/2863
To view IBio’s complete patent history, request access »

IBio Executive Team (11)

Name Title Board Seat
Martin Brenner Ph.D Chief Scientific Officer & Chief Executive Officer
Felipe Duran Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Lisa Middlebrook Chief Human Resources Officer
Stephen Kilmer Executive, Investor Relations
Nicholas DeLong Ph.D Vice President & Head, Corporate Development
You’re viewing 5 of 11 executive team members. Get the full list »

IBio Board Members (12)

Name Representing Role Since
Self Board Member
IBio Board Member
Self Board Member
Self Board Member
Self Board Member
You’re viewing 5 of 12 board members. Get the full list »

IBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

IBio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore IBio‘s full profile, request access.

Request a free trial

IBio Investments & Acquisitions (6)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
RubrYc Therapeutics 21-Sep-2022 Drug Discovery
iBio (Manufacturing Facility in Bryan, Texas) 03-Nov-2021 Buildings and Property
RubrYc Therapeutics 25-Apr-2021 Drug Discovery
Safi Biotherapeutics 02-Oct-2020 Other Pharmaceuticals and Biotechnology
iBio CDMO 23-Feb-2017 Secondary Transaction - Private Biotechnology
You’re viewing 5 of 6 investments and acquisitions. Get the full list »

Ready to get started?

Request a free trial

IBio ESG

Risk Overview

Risk Rating

Updated April, 01, 2022

32.82 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,912

Rank

Percentile

Pharmaceuticals

Industry

of 965

Rank

Percentile

Biotechnology

Subindustry

of 443

Rank

Percentile

To view IBio’s complete esg history, request access »

IBio Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
iBio (Manufacturing Facility in Bryan, Texas) 03-Nov-2021 Completed
To view IBio’s complete exits history, request access »

IBio FAQs

  • Who is the CEO of IBio?

    Martin Brenner Ph.D is the CEO of IBio.

  • Where is IBio headquartered?

    IBio is headquartered in San Diego, CA.

  • What is the size of IBio?

    IBio has 16 total employees.

  • What industry is IBio in?

    IBio’s primary industry is Pharmaceuticals.

  • Is IBio a private or public company?

    IBio is a Public company.

  • What is IBio’s stock symbol?

    The ticker symbol for IBio is IBIO.

  • What is the current stock price of IBio?

    As of 11-Oct-2024 the stock price of IBio is $2.63.

  • What is the current market cap of IBio?

    The current market capitalization of IBio is $22.7M.

  • What is IBio’s current revenue?

    The trailing twelve month revenue for IBio is $225K.

  • Who are IBio’s competitors?

    Tedor Pharma, Phyton Biotech, mAbxience, FinVector, and Crescendo Biologics are some of the 40 competitors of IBio.

  • What is IBio’s annual earnings per share (EPS)?

    IBio’s EPS for 12 months was -$6.50.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »